A Novel Calpain-Like Cysteine Protease in Type 2 Diabetes

Description:

Market: The World Health Organization (WHO) has estimated that the diabetes 2 market will more than double by 2030. In the United States type 2 diabetes affected 20.8 million people in the year 2000. The number of patients diagnosed with diabetes 2 has been continuously increasing. Approximately 90% of all diabetes cases in the United States are of type 2. With a market size of more than $11.2 billion in the US alone, there is a significant and growing market looking for better treatment options.

Competitors and Current Problems: Genome-wide screens for susceptibility genes for complex disorders have become standard procedure and genes for a number of different complex disorders have been successfully localized through linkage studies. However, there are no examples of the successful identification of a gene for a complex disease originally mapped by linkage that can be used to guide genetic studies. Thus, there is a need to provide a protocol for the identification of genes in complex disorder and further, there is a pressing need to identify the elusive type-2 diabetes susceptibility gene.

The Technology: Researchers at the University of Texas Health Science Center at Houston (UTHSC-H) have developed compositions and methods of diagnosing a propensity for type 2 diabetes mellitus, identifying compounds to treat type 2 diabetes mellitus, and new nucleic acid sequences encoding polypeptides related to type 2 diabetes mellitus. The inventors have discovered that analysis of mutations in calpain genes and gene products may be diagnostic for type 2 diabetes and have designed treatments in view of the fact that calpain mutations can cause diabetes.

UTHSC-H has secured patent protection and is interested in implementation of this technology into a clinical setting.

UTHSC-H Ref. No.: 1998-0006
Inventors: Hanis, et al.
Patent Status: Issued U.S. Patent No. 6,235,481
License Available: world-wide; exclusive or non-exclusive

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
Category(s):
Therapeutics
For Information, Contact:
Danielle Martinez
Technology Licensing Associate
University of Texas Health Science Center At Houston
danielle.r.martinez@uth.tmc.edu
Inventors:
Keywords:
© 2020. All Rights Reserved. Powered by Inteum